The world’s biggest makers of insulin are likely to make more money, not less, even after slashing prices by as much as 75% due to US government pressure.

That’s because Novo Nordisk announced price cuts to their insulin products on Tuesday, less than two weeks after rival Eli Lilly & Co. announced its own price cuts. However, both companies could avoid paying out multimillion-dollar rebates to the government’s Medicaid health-care program.

A 2021 law incentivized the companies to lower prices by removing a cap on the rebate payment, a change that kicks in next year. Federal and state governments claim the rebates from drugmakers to help offset the cost of covering prescription drugs under government programs.

Dig Deeper



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.